Registry study for first-time SIR-Spheres in liver tumors
Part of Cancer, Digestive system clinical trials.
This is an observational (real-world) study that follows people with certain unresectable liver tumors who are getting SIR-Spheres for the first time. It helps doctors understand how this treatment is used in routine care and what outcomes patients experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have confirmed unresectable liver cancer that is either hepatocellular carcinoma or colorectal cancer spread to the liver
- Your medical team says SIR-Spheres is appropriate for you as part of normal care
- You are planning to receive SIR-Spheres in the liver for the first time
- You can (or will) sign consent yourself; surrogate consent isn’t allowed
- You have not had radiation to your liver before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This study looks at how well a treatment called SIR-Spheres works for people whose colorectal cancer has spread to the liver and hasn't responded to standard treatments. SIR-Spheres are tiny radioactive beads that are injected into the liver to target tumors directly.
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors to shrink them, which may help patients become eligible for a liver transplant or surgery. It is for people with liver cancer that has not spread outside the liver.
This trial studies a targeted liver radiation procedure that uses tiny radioactive beads to treat colon cancer spread mostly in the liver. It may help people whose liver tumors cannot be removed or treated with other common local treatments, but it has several safety and “screening” checks.
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.